Topical Cream SNG100 for Treatment in Moderate Atopic Dermatitis Subjects.
Status:
Not yet recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The investigators aimed to understand better the efficacy in a randomized, double-blind,
intraindividual design trial in 66 participants with AD treated with SNG100, and 2 different
strengths of topical steroids hydrocortisone and the medium potent mometasone furoate cream.